1. Home
  2. TRMD vs ADMA Comparison

TRMD vs ADMA Comparison

Compare TRMD & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TORM plc

TRMD

TORM plc

HOLD

Current Price

$29.68

Market Cap

2.9B

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$8.78

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRMD
ADMA
Founded
1889
2004
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
2016
2012

Fundamental Metrics

Financial Performance
Metric
TRMD
ADMA
Price
$29.68
$8.78
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$35.00
$25.67
AVG Volume (30 Days)
906.2K
3.3M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
6.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.19
Revenue
N/A
$42,219,783.00
Revenue This Year
N/A
$27.46
Revenue Next Year
N/A
$22.11
P/E Ratio
$9.61
$42.74
Revenue Growth
N/A
43.85
52 Week Low
$16.37
$7.21
52 Week High
$35.33
$22.20

Technical Indicators

Market Signals
Indicator
TRMD
ADMA
Relative Strength Index (RSI) 48.57 53.11
Support Level $29.15 $7.38
Resistance Level $31.76 $11.42
Average True Range (ATR) 0.81 0.30
MACD -0.08 0.16
Stochastic Oscillator 43.09 93.43

Price Performance

Historical Comparison
TRMD
ADMA

About TRMD TORM plc

TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: